U.S. flag

An official website of the United States government

Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 11

1.

Molecular signature predictive of long-term liver fibrosis progression to inform anti-fibrotic drug development

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Expression profiling by array
5 related Platforms
917 Samples
Download data
Series
Accession:
GSE85550
ID:
200085550

PubMed Full text in PMC Similar studies Analyze with GEO2R

2.

Expression profiling of prognostic liver signature in clinical fibrotic liver tissues cultured with various anti-fibrotic and chemopreventive agents

(Submitter supplied) Background/Aims: There is a major unmet need to assess prognostic impact of anti-fibrotics in clinical trials due to the slow rate of liver fibrosis progression. We aimed to develop a surrogate biomarker to predict future fibrosis progression. Methods: A Fibrosis Progression Signature (FPS) was defined to predict fibrosis progression within 5 years in HCV and NAFLD patients with no to minimal fibrosis at baseline (n=421), and validated in an independent NAFLD cohort (n=78). more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL19886
293 Samples
Download data: TXT
Series
Accession:
GSE182065
ID:
200182065

PubMed Full text in PMC Similar studies Analyze with GEO2R

3.

Prognostic liver signature profiles in biopsy tissues from non-alcoholic fatty liver disease patients followed for fibrosis progression

(Submitter supplied) Background/Aims: There is a major unmet need to assess prognostic impact of anti-fibrotics in clinical trials due to the slow rate of liver fibrosis progression. We aimed to develop a surrogate biomarker to predict future fibrosis progression. Methods: A Fibrosis Progression Signature (FPS) was defined to predict fibrosis progression within 5 years in HCV and NAFLD patients with no to minimal fibrosis at baseline (n=421), and validated in an independent NAFLD cohort (n=78). more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL30511
156 Samples
Download data: TXT
Series
Accession:
GSE182060
ID:
200182060

PubMed Full text in PMC Similar studies Analyze with GEO2R

4.

Expression profiling of Prognostic Liver Signature and fibrosis-related genes in clinical fibrotic liver tissue cultured with various anti-fibrotic agents

(Submitter supplied) Background/Aims: There is a major unmet need to assess prognostic impact of anti-fibrotics in clinical trials due to the slow rate of liver fibrosis progression. We aimed to develop a surrogate biomarker to predict future fibrosis progression. Methods: A Fibrosis Progression Signature (FPS) was defined to predict fibrosis progression within 5 years in HCV and NAFLD patients with no to minimal fibrosis at baseline (n=421), and validated in an independent NAFLD cohort (n=78). more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL30481
9 Samples
Download data: TXT
Series
Accession:
GSE181538
ID:
200181538

PubMed Full text in PMC Similar studies Analyze with GEO2R

5.

Transcriptome profiles of liver biopsy tissues before and after cenicriviroc treatment in patients with non-alcoholic steatohepatitis

(Submitter supplied) Non-alcoholic steatohepatitis (NASH) is a sharpy emerging cause of liver fibrosis and cancer that leads to poor prognosis of the patients. A dual CCR2/CCR5 inhibitor, cenicriviroc, was tested in a phase IIb CENTAUR trial for its efficacy to reduce fibrosis.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL21697
38 Samples
Download data: TXT
Series
Accession:
GSE175448
ID:
200175448

PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector

6.

Prognostic Liver Signature profiles in biopsy tissues from non-alcoholic fatty liver disease (NAFLD) patients in Japan

(Submitter supplied) Background/Aims: There is a major unmet need to assess prognostic impact of anti-fibrotics in clinical trials due to the slow rate of liver fibrosis progression. We aimed to develop a surrogate biomarker to predict future fibrosis progression. Methods: A Fibrosis Progression Signature (FPS) was defined to predict fibrosis progression within 5 years in HCV and NAFLD patients with no to minimal fibrosis at baseline (n=421), and validated in an independent NAFLD cohort (n=78). more...
Organism:
Homo sapiens
Type:
Other
Platform:
GPL19886
31 Samples
Download data: TXT
Series
Accession:
GSE161841
ID:
200161841

PubMed Full text in PMC Similar studies Analyze with GEO2R

7.

Prognostic Liver Signature profiles in biopsy tissues from non-alcoholic fatty liver disease (NAFLD) patients in the U.S.

(Submitter supplied) Background/Aims: There is a major unmet need to assess prognostic impact of anti-fibrotics in clinical trials due to the slow rate of liver fibrosis progression. We aimed to develop a surrogate biomarker to predict future fibrosis progression. Methods: A Fibrosis Progression Signature (FPS) was defined to predict fibrosis progression within 5 years in HCV and NAFLD patients with no to minimal fibrosis at baseline (n=421), and validated in an independent NAFLD cohort (n=78). more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL19886
309 Samples
Download data: TXT
Series
Accession:
GSE150734
ID:
200150734

PubMed Full text in PMC Similar studies Analyze with GEO2R

8.

Prognostic Liver Signature profiles in biopsy tissues from chronic hepatitis C patients followed for fibrosis progression

(Submitter supplied) Background/Aims: There is a major unmet need to assess prognostic impact of anti-fibrotics in clinical trials due to the slow rate of liver fibrosis progression. We aimed to develop a surrogate biomarker to predict future fibrosis progression. Methods: A Fibrosis Progression Signature (FPS) was defined to predict fibrosis progression within 5 years in HCV and NAFLD patients with no to minimal fibrosis at baseline (n=421), and validated in an independent NAFLD cohort (n=78). more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL19886
19 Samples
Download data: TXT
Series
Accession:
GSE85548
ID:
200085548

PubMed Full text in PMC Similar studies Analyze with GEO2R

9.

Prognostic Liver Signature profiles in biopsy tissues from chronic hepatitis C patients with HIV co-infection followed for fibrosis progression

(Submitter supplied) Background/Aims: There is a major unmet need to assess prognostic impact of anti-fibrotics in clinical trials due to the slow rate of liver fibrosis progression. We aimed to develop a surrogate biomarker to predict future fibrosis progression. Methods: A Fibrosis Progression Signature (FPS) was defined to predict fibrosis progression within 5 years in HCV and NAFLD patients with no to minimal fibrosis at baseline (n=421), and validated in an independent NAFLD cohort (n=78). more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL17230
24 Samples
Download data: TXT
Series
Accession:
GSE85547
ID:
200085547

PubMed Full text in PMC Similar studies Analyze with GEO2R

10.

Prognostic Liver Signature profiles in post-transplant liver biopsy tissues from chronic hepatitis C patients

(Submitter supplied) Background/Aims: There is a major unmet need to assess prognostic impact of anti-fibrotics in clinical trials due to the slow rate of liver fibrosis progression. We aimed to develop a surrogate biomarker to predict future fibrosis progression. Methods: A Fibrosis Progression Signature (FPS) was defined to predict fibrosis progression within 5 years in HCV and NAFLD patients with no to minimal fibrosis at baseline (n=421), and validated in an independent NAFLD cohort (n=78). more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL17230
38 Samples
Download data: TXT
Series
Accession:
GSE85546
ID:
200085546

PubMed Full text in PMC Similar studies Analyze with GEO2R

11.

Therapeutic Inhibition of Inflammatory Monocyte Recruitment Reduces Steatohepatitis and Liver Fibrosis

(Submitter supplied) The CCR2/CCR5 inhibitor cenicriviroc blocks infiltration of inflammatory monocytes into the liver, thereby reducing NASH progression and fibrosis.
Organism:
Mus musculus
Type:
Expression profiling by high throughput sequencing
Platform:
GPL17021
8 Samples
Download data: TXT, XLSX
Series
Accession:
GSE98782
ID:
200098782

PubMed Similar studies SRA Run Selector

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filters: Manage Filters

db=gds|term=|query=1|qty=3|blobid=MCID_6748e45c462e1a751e13b09f|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Important Links

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Genes & Expression > Gene Expression Omnibus (GEO) Datasets
Support Center